Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Example of PR for Proof Of Concept

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Oct 24, 2022 11:42am

93 Views

Post# 35043778

RE:RE:RE:RE:RE:RE:Example of PR for Proof Of Concept

You are not stupid but the market sure appears to be a bit off its rocker. TH is worth more than the current price just on its legacy drugs. Anyone buying now gets the cancer opportunity f r free, and maybe NASH too. Neitehr may amount to anything but either one, particularly cancer, could produce enormous returns. If cancer was announced to be a dud, the stock would likely fall for a while as those in it for cancer sell their stakes but it should then bounce back to a higher price than currently as the company could move into a profitable state pretty quickly as it shed expenses related to its cancer efforts.